Interviews & Webcasts

March 18, 2021: BioStock article: Saniona’s CEO on year-end results and the company’s long-term goals. Link. 

March 10, 2021: BioStock article: Saniona on the positive feedback from FDA. Link. 

March 4, 2021: BioStock article: Saniona´s CMO on the FDA’s Orphan Drug Designation for Tesomet in Prader-Willi Syndrome. Link. 

February 4, 2021: BioStock article: Saniona's Chief Communications Officer on the importance of communication. Link.

January 12, 2021: BioStock article: Saniona's CEO on the plans for 2021. Link. 

November 25, 2020: BioStock article: Strong signals from Saniona in rare disease. Link.

November 24, 2020: Investor Call on positive topline results from Tesomet Phase 2 open-label extension study in hypothalamic obesity, with Principal Investigator Ulla Feldt-Rasmussen, M.D., DMSc, (Department of Medical Endocrinology and Metabolism, Rigshospitalet, Copenhagen University Hospital). Link to webcast.

October 20, 2020: BioStock interview with Chairman of the Board J. Donald deBethizy. Link to interview

August 14, 2020: Conference call on $65 million directed issue of shares. Link to webcast

July 20, 2020: BioStock interview with President and CEO Rami Levin. Link to interview

May 4, 2020: Podcast interview by The Raymond A. Wood Foundation with Saniona President and CEO Rami Levin. Link to podcast

April 28, 2020: Investor Call on positive topline results from Phase 2 trial with Tesomet in Hypothalamic Obesity, with Principal Investigator Ulla Feldt-Rasmussen, M.D., DMSc, (Department of Medical Endocrinology and Metabolism, Rigshospitalet, Copenhagen University Hospital). Link to webcast